Table 4 Mortality and overall survival in 181 node-negative breast cancer patients after different adjuvant systemic therapies or no therapy
Subgroup | Â | n | Mortality (n [%]) | OS (P) |
|---|---|---|---|---|
Chemotherapy (n = 61) | ||||
   c-myc | Amplified | 19 | 1 (5.3) | 0.7442 |
| Â | Nonamplified | 42 | 3 (7.1) | Â |
HER-2/neu | Amplified | 26 | 0 (0.0) | 0.1042 |
| Â | Nonamplified | 35 | 4 (11.4) | Â |
Endocrine therapy (n= 99) | ||||
   c-myc | Amplified | 15 | 1 (6.7) | 0.9846 |
| Â | Nonamplified | 84 | 6 (7.1) | Â |
HER-2/neu | Amplified | 22 | 2 (9.1) | 0.8307 |
| Â | Nonamplified | 77 | 5 (6.5) | Â |
No therapy (n = 21) | ||||
   c-myc | Amplified | 5 | 2 (40.0) | 0.0098* |
| Â | Nonamplified | 16 | 1 (6.3) | Â |
HER-2/neu | Amplified | 7 | 1 (14.3) | 0.5649 |
| Â | Nonamplified | 14 | 2 (14.3) | Â |